TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
TransitionCHF aims to recruit a unique cohort of patients with asymptomatic left ventricular dysfunction (NYHA I) to study the progression to symptomatic (>NYHA I) HF and to identify parameters/ biomarkers promoting and predicting the individual risk of transition. Results from TransitionCHF Cohort Study will inform and refine current treatment guidelines. The implementation of common patient data sets and biobanking standards will enable data and biomaterial sharing with other DZHK study groups. This study will set the standard for a unique DZHK heart failure database and Biobank for innovative preclinical and clinical trials.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 95 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The DZHK TransitionCHF Cohort Study will include patients with systolic dysfunction (NYHA I), i.e. (1) patients without a history of HF symptoms and (2) patients who reversed from symptomatic HF. Patients will be recruited prospectively at the seven participating DZHK centres and eight external partners from the ALKK network (German Working Group of Leading Hospital-based Cardiologists) and university hospitals.
Asymptomatic systolic dysfunction (defined as: ejection fraction < 40% by echocardiography or MRI; documented within the last 3 months prior to baseline visit)
No history of hospitalization for heart failure (defined as hospitalisation with symptoms of heart failure requiring initiation of therapy with a loop diuretic or escalation of a pre-existing loop diuretic therapy within 48 hours after hospital admission)
No heart failure symptoms (NYHA II, III or IV) upon inclusion
6MWD ≥ 80% of reference values
Written informed consent
Age ≥ 18 years
Symptomatic heart failure (NYHA>I) at baseline visit
Any significant valvular disease (> 2nd degree)
Severe pulmonary disease (e. g. FEV1 < 70% of normal limit)
Severe renal disease (GFR < 15 ml/min)
ejection fraction at baseline visit ≥ 50% by echocardiography or MRI
Life expectancy < 1 year
Myocardial infarction within the last 3 months
Planned cardiac surgical intervention within 3 months after inclusion
Geographical reasons (e. g. patients living outside Germany or planning to move abroad)
Inability to give informed consent (e. g. mental disorders)
Therapy with loop diuretics (e. g. torasemide, furosemide, piretanide)